Please login to the form below

Not currently logged in
Email:
Password:

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe
AbbVie logo

The European Medicines Agency (EMA) has recommended two AbbVie drugs for the treatment of hepatitis C in adults.

AbbVie's Exviera (dasabuvir) and combination treatment Viekirax (ombitasvir, paritaprevir and ritonavir) both received backing from the EMA's Committee for Medicinal Products for Human Use (CHMP) in its latest round of opinions published at the end of last week.

The drugs are part of a new generation of medicines for chronic hepatitis C infection that have high cure rates and improved convenience for patients, reshaping the way the disease is treated.

Both Exviera and Viekirax block the action of proteins that are essential for HCV replication. Exviera targets the protein NS5B while Viekirax targets the proteins NS5A and NS3/4A.

Over the last year, the EMA has recommended marketing authorisations for four new medicines for the treatment of HCV, including GSK's Revolade (eltrombopag) and Janssen's Olysio (simeprevir).

Leading the field though is Gilead Sciences, which is breaking records with its drug Sovaldi (sofosbuvir), while Harvoni – a combination of Sovaldi and ledipasvir – is also set for big success.

The addition of AbbVie's two treatments will provide a further option for patients with hepatitis C, which remains a European health challenge, affecting between 0.4% and 3.5% of the population in different EU member states. It is the most common single cause of liver transplantation in the EU.

24th November 2014

From: Sales, Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....